{"title":"Synovial sarcoma: A decade of insights from a tertiary referral center","authors":"Anupam Lahiri , Himanshu Rohela","doi":"10.1016/j.jorep.2024.100497","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Synovial sarcoma (SS) constitutes approximately 10 % of all sarcomas, primarily affecting younger individuals but found across diverse anatomical sites with a propensity for lung metastases.</div></div><div><h3>Objective</h3><div>This retrospective study aimed to assess clinical characteristics, survival outcomes, and treatment efficacy in 39 patients with synovial sarcoma treated at an Indian tertiary referral center from 2009 to 2019.</div></div><div><h3>Methods</h3><div>Data encompassed demographics, disease features, treatments, and outcomes retrieved from institutional records. Survival analyses included Kaplan-Meier estimates for overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS).</div></div><div><h3>Results</h3><div>The cohort, predominantly male (51.3 %) with a median age of 36.4 years, featured tumors mostly deep-seated (82.5 %) and located in extremities (82.1 %). Surgical excision with clear margins was achieved in 97.4 % of cases, supplemented by adjuvant radiotherapy in 74.4 %. Five-year and ten-year OS rates were 57 % and 26.3 %, respectively. Local recurrence occurred in 15.3 % of cases, with 48.7 % developing distant metastases, primarily to the lungs. Factors significantly impacting survival included tumor depth, disease stage, and subcentimeter nodules on chest imaging.</div></div><div><h3>Conclusion</h3><div>This study provides comprehensive insights into synovial sarcoma's clinical profile and treatment outcomes at an Indian tertiary center. Despite aggressive surgical and adjuvant therapies, recurrence rates remain notable, emphasizing the need for advanced therapeutic strategies and prospective studies to optimize patient management and outcomes.</div></div>","PeriodicalId":100818,"journal":{"name":"Journal of Orthopaedic Reports","volume":"4 4","pages":"Article 100497"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Orthopaedic Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2773157X24001929","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Synovial sarcoma (SS) constitutes approximately 10 % of all sarcomas, primarily affecting younger individuals but found across diverse anatomical sites with a propensity for lung metastases.
Objective
This retrospective study aimed to assess clinical characteristics, survival outcomes, and treatment efficacy in 39 patients with synovial sarcoma treated at an Indian tertiary referral center from 2009 to 2019.
Methods
Data encompassed demographics, disease features, treatments, and outcomes retrieved from institutional records. Survival analyses included Kaplan-Meier estimates for overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS).
Results
The cohort, predominantly male (51.3 %) with a median age of 36.4 years, featured tumors mostly deep-seated (82.5 %) and located in extremities (82.1 %). Surgical excision with clear margins was achieved in 97.4 % of cases, supplemented by adjuvant radiotherapy in 74.4 %. Five-year and ten-year OS rates were 57 % and 26.3 %, respectively. Local recurrence occurred in 15.3 % of cases, with 48.7 % developing distant metastases, primarily to the lungs. Factors significantly impacting survival included tumor depth, disease stage, and subcentimeter nodules on chest imaging.
Conclusion
This study provides comprehensive insights into synovial sarcoma's clinical profile and treatment outcomes at an Indian tertiary center. Despite aggressive surgical and adjuvant therapies, recurrence rates remain notable, emphasizing the need for advanced therapeutic strategies and prospective studies to optimize patient management and outcomes.
背景滑膜肉瘤(SS)约占所有肉瘤的10%,主要影响年轻人,但发现于不同的解剖部位,有肺转移倾向。 ObjectiveThis retrospective study aimed to assess clinical characteristics, survival outcomes, and treatment efficacy in 39 patients with synovial sarcoma treated at an Indian tertiary referral center from 2009 to 2019.MethodsData encompassed demographics, disease features, treatments, and outcomes retrieved from institutional records.这项回顾性研究旨在评估2009年至2019年在印度一家三级转诊中心接受治疗的39例滑膜肉瘤患者的临床特征、生存结果和治疗效果。生存分析包括总生存期(OS)、无病生存期(DFS)、无局部复发生存期(LRFS)和无远处转移生存期(DMFS)的卡普兰-梅耶估计值。结果该组患者主要为男性(51.3%),中位年龄为36.4岁,肿瘤大多位于深部(82.5%)和四肢(82.1%)。97.4%的病例可进行边缘清晰的手术切除,74.4%的病例辅以辅助放疗。五年和十年的OS率分别为57%和26.3%。15.3%的病例出现局部复发,48.7%出现远处转移,主要是肺部。影响生存率的重要因素包括肿瘤深度、疾病分期和胸部影像学检查中的亚厘米结节。尽管采取了积极的手术和辅助疗法,但复发率仍然很高,这强调了先进治疗策略和前瞻性研究的必要性,以优化患者管理和治疗效果。